secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enovis CORP (ENOV)
CIK:        0001420800
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001420800-22-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enovis Q2 revenue $395M (+11%), adjusted EPS $0.59 (+44%), full-year guidance updated
--------------------------------------------------------------------------------

- Reported EPS from continuing ops $2.21; adjusted EPS $0.59 vs $0.41 YoY, includes ~$0.10 one-time tax benefit.
- Organic growth 3% (5% per-day); adjusted EBITDA $56M, +11% YoY, with $2M currency pressure.
- Completed acquisitions of Insight Medical Systems (ARVIS AR surgical guidance) and 360 Med Care (Australian distributor).
- Updated FY2022 outlook: organic growth 6-9% reaffirmed; adjusted EBITDA $235-255M; adjusted EPS $2.15-$2.35.
- Currency headwinds expected to impact full-year; Q2 tax planning benefit lifted adjusted EPS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420800/000142080022000016/0001420800-22-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420800/000142080022000016/cfx-20220804.htm
  HTML page:      https://secwatch.observer/filing/0001420800-22-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer